CLINICAL/METHODICAL ISSUE: High prevalence of prostate cancer with multifocality and biological heterogeneity. Insufficient conventional urological diagnostics. Discrimination between significant and insignificant cancer needed. STANDARD DIAGNOSTIC METHODS: Digital rectal examination, prostate-specific antigen (PSA) serum level, systematic transrectal ultrasound (TRUS)-guided prostate biopsy. METHODICAL INNOVATIONS: Multiparametric magnetic resonance imaging (mpMRI) including T2-weighted (T2w), diffusion-weighted and dynamic contrast-enhanced MRI according to the prostate imaging reporting and data system (PIRADS), MR-targeted biopsy, most frequently MR/TRUS image fusion biopsy. FINDINGS AND PERFORMANCE: Prostate cancer is characterized by low signal intensity on T2w MRI, restricted water diffusion and pronounced and early uptake of contrast enhancement. Sensitivity and specificity according to the current literature are ca. 80% and 90%, respectively. PRACTICAL RECOMMENDATIONS: In cases of suspected prostate cancer, most accurate are mpMRI according to PIRADS and in cases of positive findings, MRI-targeted biopsy, most frequently as MRI/TRUS image fusion biopsy.
CLINICAL/METHODICAL ISSUE: High prevalence of prostate cancer with multifocality and biological heterogeneity. Insufficient conventional urological diagnostics. Discrimination between significant and insignificant cancer needed. STANDARD DIAGNOSTIC METHODS: Digital rectal examination, prostate-specific antigen (PSA) serum level, systematic transrectal ultrasound (TRUS)-guided prostate biopsy. METHODICAL INNOVATIONS: Multiparametric magnetic resonance imaging (mpMRI) including T2-weighted (T2w), diffusion-weighted and dynamic contrast-enhanced MRI according to the prostate imaging reporting and data system (PIRADS), MR-targeted biopsy, most frequently MR/TRUS image fusion biopsy. FINDINGS AND PERFORMANCE: Prostate cancer is characterized by low signal intensity on T2w MRI, restricted water diffusion and pronounced and early uptake of contrast enhancement. Sensitivity and specificity according to the current literature are ca. 80% and 90%, respectively. PRACTICAL RECOMMENDATIONS: In cases of suspected prostate cancer, most accurate are mpMRI according to PIRADS and in cases of positive findings, MRI-targeted biopsy, most frequently as MRI/TRUS image fusion biopsy.
Entities:
Keywords:
Multiparametric MRI; PIRADS; Prostate cancer
Authors: Jeffrey J Tosoian; Stacy Loeb; Jonathan I Epstein; Baris Turkbey; Peter L Choyke; Edward M Schaeffer Journal: Am Soc Clin Oncol Educ Book Date: 2016
Authors: David Bonekamp; Michael A Jacobs; Riham El-Khouli; Dan Stoianovici; Katarzyna J Macura Journal: Radiographics Date: 2011 May-Jun Impact factor: 5.333
Authors: Daniel I Glazer; Elmira Hassanzadeh; Andriy Fedorov; Olutayo I Olubiyi; Shayna S Goldberger; Tobias Penzkofer; Trevor A Flood; Paul Masry; Robert V Mulkern; Michelle S Hirsch; Clare M Tempany; Fiona M Fennessy Journal: Abdom Radiol (NY) Date: 2017-03
Authors: Jennifer R Rider; Fredrik Sandin; Ove Andrén; Peter Wiklund; Jonas Hugosson; Pär Stattin Journal: Eur Urol Date: 2012-08-10 Impact factor: 20.096
Authors: Baris Turkbey; Anna M Brown; Sandeep Sankineni; Bradford J Wood; Peter A Pinto; Peter L Choyke Journal: CA Cancer J Clin Date: 2015-11-23 Impact factor: 508.702
Authors: Marcin Popiolek; Jennifer R Rider; Ove Andrén; Sven-Olof Andersson; Lars Holmberg; Hans-Olov Adami; Jan-Erik Johansson Journal: Eur Urol Date: 2012-10-13 Impact factor: 20.096